Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inactivated poliovirus type 2 capsid protein is a component of the inactivated poliovirus vaccine (IPV) used to protect against poliomyelitis. The capsid proteins, including VP0 (which is later cleaved into VP4 and VP2), VP1, and VP3, are responsible for receptor binding and antigenicity. Inactivation, typically with formalin, renders the virus non-infectious while preserving its antigenic properties, allowing it to induce an immune response without causing disease. While wild poliovirus type 2 has been eradicated, inactivated poliovirus type 2 capsid protein remains crucial for maintaining immunity and preventing the re-emergence of poliomyelitis.
The inactivated poliovirus type 2 capsid protein elicits an antibody response, leading to the neutralization of the virus upon subsequent exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poliovirus Type 2 Capsid Protein (Inactivated).